Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 16.76 EUR Market Closed
Market Cap: 490.1m EUR
Have any thoughts about
Medincell SA?
Write Note

Medincell SA
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Medincell SA
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Medincell SA
PAR:MEDCL
Total Current Liabilities
€16.5m
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Sanofi SA
PAR:SAN
Total Current Liabilities
€30B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ipsen SA
PAR:IPN
Total Current Liabilities
€1.7B
CAGR 3-Years
14%
CAGR 5-Years
0%
CAGR 10-Years
17%
Vetoquinol SA
PAR:VETO
Total Current Liabilities
€138.8m
CAGR 3-Years
-4%
CAGR 5-Years
11%
CAGR 10-Years
5%
Virbac SA
PAR:VIRP
Total Current Liabilities
€530.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boiron SA
PAR:BOI
Total Current Liabilities
€113.9m
CAGR 3-Years
-10%
CAGR 5-Years
-4%
CAGR 10-Years
-1%
No Stocks Found

Medincell SA
Glance View

Market Cap
487.2m EUR
Industry
Pharmaceuticals

MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.

MEDCL Intrinsic Value
21.71 EUR
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Medincell SA's Total Current Liabilities?
Total Current Liabilities
16.5m EUR

Based on the financial report for Mar 31, 2024, Medincell SA's Total Current Liabilities amounts to 16.5m EUR.

What is Medincell SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
16%

Over the last year, the Total Current Liabilities growth was -71%. The average annual Total Current Liabilities growth rates for Medincell SA have been 7% over the past three years , 16% over the past five years .

Back to Top